The microbial world has been a rich source of medicines, but our ability to explore the full potential of the microbes both in us and around us has been limited by technology and the difficulty of culturing most microbes in a lab. Biosortia Microbiomics has developed a platform for finding, amplifying, and screening microbes as a potential source of novel, small molecule drugs. We spoke to Ross Youngs, CEO and founder of Biosortia, about the case for exploring various microbiomes to discover new small molecule drugs, how the company’s platform technology enables it to investigate a much broader range of microbes, and its business model for capitalizing on the discoveries it makes.
Using Technology to Regain Abilities after Spinal Cord Injury
Why Drug Developers Have a Growing Interest in Targeting Mitochondria
Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates
Targeting a Multitude of CIN in Cancer Cells
The Year in Biotech and What’s Ahead in 2024
Transforming Healthcare with Data
Realizing the Promise of IL-2 Therapies with AI
Unlocking Real-World Data to Improve Outcomes
A Silicon Valley Entrepreneur Investing at the Intersection of Tech and Biotech
A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery
Detecting Alzheimer’s Disease Early through a Blood Test
Addressing Supply-Chain Challenges Underlying Drug Shortages with Synthetic Biology
Building Better and More Affordable Vaccines
Overcoming Resistance to Targeted Therapies
Using Tumor Gene Therapy to Overcome Barriers to Immunotherapies
Using AI to Generate Mini-Protein Therapeutics
Inhibiting Cell Death to Preserve Vision in Retinal Diseases
Leveraging Generative AI to Design Therapeutic Antibodies
Managing Pain without Addiction
Using AI to Match Cancer Patients to their Best Treatment Options
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
All In The Mind